Nephrotic syndrome membranous nephropathy stage II is not considered serious, but it should be actively treated to avoid aggravation of pathological changes and progression of renal function.
Membranous nephropathy is a pathological type of nephrotic syndrome, which is prevalent in middle-aged and elderly people. Stage II of membranous nephropathy is manifested in light microscopy as thickening of the basement membrane or vacuolar degeneration, and there is a deposition of electron-dense material under the epithelium, and immunofluorescence manifests that the immunocomplexes are distributed diffusely in the form of granules on the epithelial side of the basement membrane, sometimes in the form of a pseudo-linear pattern.
Generally, this stage is not considered serious, and the treatment is based on 24-hour proteinuria, blood albumin, blood creatinine, and anti-phospholipase A2 receptor antibody levels, and the treatment plan is formulated, such as choosing renin-angiotensin-aldosterone receptor antagonists (valdecoxib, benadryl, etc.), immunosuppressants (tacrolimus, cyclophosphamide, etc.), and rituximab, etc., and the prognosis is usually OK.
However, the disease may continue to progress, eventually leading to elevated creatinine and even uremia.
Patients with nephrotic syndrome membranous nephropathy stage II are advised to consult regular hospitals in time and standardize the treatment under the guidance of physicians, and the above medications should be used in accordance with the doctor’s instructions, not without authorization, so as not to aggravate the condition.